nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.518	0.708	CbGbCtD
Leflunomide—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.214	0.292	CbGbCtD
Leflunomide—Iron deficiency anaemia—Riluzole—amyotrophic lateral sclerosis	0.00891	0.0404	CcSEcCtD
Leflunomide—Salivary gland enlargement—Riluzole—amyotrophic lateral sclerosis	0.00729	0.033	CcSEcCtD
Leflunomide—Skin nodule—Riluzole—amyotrophic lateral sclerosis	0.00729	0.033	CcSEcCtD
Leflunomide—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.00653	0.0296	CcSEcCtD
Leflunomide—Niflumic Acid—PLA2G4A—amyotrophic lateral sclerosis	0.00572	0.827	CrCbGaD
Leflunomide—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.00543	0.0246	CcSEcCtD
Leflunomide—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.00543	0.0246	CcSEcCtD
Leflunomide—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00485	0.022	CcSEcCtD
Leflunomide—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00432	0.0196	CcSEcCtD
Leflunomide—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00401	0.0182	CcSEcCtD
Leflunomide—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00385	0.0174	CcSEcCtD
Leflunomide—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0168	CcSEcCtD
Leflunomide—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0151	CcSEcCtD
Leflunomide—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00322	0.0146	CcSEcCtD
Leflunomide—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00319	0.0144	CcSEcCtD
Leflunomide—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00312	0.0141	CcSEcCtD
Leflunomide—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0137	CcSEcCtD
Leflunomide—DHODH—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.00295	0.073	CbGpPWpGaD
Leflunomide—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0133	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—GRN—amyotrophic lateral sclerosis	0.00288	0.0712	CbGpPWpGaD
Leflunomide—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00286	0.013	CcSEcCtD
Leflunomide—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0123	CcSEcCtD
Leflunomide—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00262	0.0119	CcSEcCtD
Leflunomide—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0118	CcSEcCtD
Leflunomide—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00256	0.0116	CcSEcCtD
Leflunomide—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00244	0.0111	CcSEcCtD
Leflunomide—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00241	0.0109	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00229	0.0566	CbGpPWpGaD
Leflunomide—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0101	CcSEcCtD
Leflunomide—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00221	0.01	CcSEcCtD
Leflunomide—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00214	0.0097	CcSEcCtD
Leflunomide—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00964	CcSEcCtD
Leflunomide—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00928	CcSEcCtD
Leflunomide—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00917	CcSEcCtD
Leflunomide—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.002	0.00907	CcSEcCtD
Leflunomide—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00896	CcSEcCtD
Leflunomide—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00876	CcSEcCtD
Leflunomide—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00843	CcSEcCtD
Leflunomide—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00829	CcSEcCtD
Leflunomide—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00829	CcSEcCtD
Leflunomide—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00796	CcSEcCtD
Leflunomide—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00172	0.0078	CcSEcCtD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—HNRNPA1—amyotrophic lateral sclerosis	0.00171	0.0424	CbGpPWpGaD
Leflunomide—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00766	CcSEcCtD
Leflunomide—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00741	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00688	CcSEcCtD
Leflunomide—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00685	CcSEcCtD
Leflunomide—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00666	CcSEcCtD
Leflunomide—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00655	CcSEcCtD
Leflunomide—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00615	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—MPP5—amyotrophic lateral sclerosis	0.00135	0.0334	CbGpPWpGaD
Leflunomide—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00606	CcSEcCtD
Leflunomide—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00602	CcSEcCtD
Leflunomide—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00589	CcSEcCtD
Leflunomide—AHR—Adipogenesis—RARA—amyotrophic lateral sclerosis	0.00129	0.0319	CbGpPWpGaD
Leflunomide—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00575	CcSEcCtD
Leflunomide—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00575	CcSEcCtD
Leflunomide—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00564	CcSEcCtD
Leflunomide—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00561	CcSEcCtD
Leflunomide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00553	CcSEcCtD
Leflunomide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00547	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MAPT—amyotrophic lateral sclerosis	0.0012	0.0298	CbGpPWpGaD
Leflunomide—Niflumic Acid—PTGS2—amyotrophic lateral sclerosis	0.00119	0.173	CrCbGaD
Leflunomide—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00538	CcSEcCtD
Leflunomide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00538	CcSEcCtD
Leflunomide—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00532	CcSEcCtD
Leflunomide—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00521	CcSEcCtD
Leflunomide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00516	CcSEcCtD
Leflunomide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00513	CcSEcCtD
Leflunomide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00513	CcSEcCtD
Leflunomide—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00503	CcSEcCtD
Leflunomide—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.0011	0.005	CcSEcCtD
Leflunomide—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.005	CcSEcCtD
Leflunomide—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00499	CcSEcCtD
Leflunomide—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00489	CcSEcCtD
Leflunomide—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00485	CcSEcCtD
Leflunomide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00484	CcSEcCtD
Leflunomide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00481	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—PTPRF—amyotrophic lateral sclerosis	0.00106	0.0262	CbGpPWpGaD
Leflunomide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00479	CcSEcCtD
Leflunomide—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00463	CcSEcCtD
Leflunomide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00462	CcSEcCtD
Leflunomide—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00461	CcSEcCtD
Leflunomide—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00461	CcSEcCtD
Leflunomide—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00457	CcSEcCtD
Leflunomide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.001	0.00455	CcSEcCtD
Leflunomide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.001	0.00454	CcSEcCtD
Leflunomide—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000999	0.00453	CcSEcCtD
Leflunomide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000996	0.00452	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ATXN2—amyotrophic lateral sclerosis	0.000962	0.0238	CbGpPWpGaD
Leflunomide—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00436	CcSEcCtD
Leflunomide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00095	0.0043	CcSEcCtD
Leflunomide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000943	0.00428	CcSEcCtD
Leflunomide—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000918	0.00416	CcSEcCtD
Leflunomide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000916	0.00415	CcSEcCtD
Leflunomide—Chills—Riluzole—amyotrophic lateral sclerosis	0.000912	0.00413	CcSEcCtD
Leflunomide—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00411	CcSEcCtD
Leflunomide—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000898	0.00407	CcSEcCtD
Leflunomide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00089	0.00404	CcSEcCtD
Leflunomide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000885	0.00401	CcSEcCtD
Leflunomide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000872	0.00395	CcSEcCtD
Leflunomide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000866	0.00393	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—MAPT—amyotrophic lateral sclerosis	0.000859	0.0213	CbGpPWpGaD
Leflunomide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00388	CcSEcCtD
Leflunomide—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000851	0.00386	CcSEcCtD
Leflunomide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000821	0.00372	CcSEcCtD
Leflunomide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000818	0.00371	CcSEcCtD
Leflunomide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000808	0.00366	CcSEcCtD
Leflunomide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000798	0.00362	CcSEcCtD
Leflunomide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000795	0.0036	CcSEcCtD
Leflunomide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00359	CcSEcCtD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—SQSTM1—amyotrophic lateral sclerosis	0.000789	0.0195	CbGpPWpGaD
Leflunomide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00354	CcSEcCtD
Leflunomide—Cough—Riluzole—amyotrophic lateral sclerosis	0.000772	0.0035	CcSEcCtD
Leflunomide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000764	0.00346	CcSEcCtD
Leflunomide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000753	0.00341	CcSEcCtD
Leflunomide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000753	0.00341	CcSEcCtD
Leflunomide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000753	0.00341	CcSEcCtD
Leflunomide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000751	0.0034	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000748	0.00339	CcSEcCtD
Leflunomide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000744	0.00337	CcSEcCtD
Leflunomide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00334	CcSEcCtD
Leflunomide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.000732	0.0181	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000722	0.00327	CcSEcCtD
Leflunomide—Infection—Riluzole—amyotrophic lateral sclerosis	0.000717	0.00325	CcSEcCtD
Leflunomide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000708	0.00321	CcSEcCtD
Leflunomide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000707	0.0032	CcSEcCtD
Leflunomide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000705	0.00319	CcSEcCtD
Leflunomide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000701	0.00318	CcSEcCtD
Leflunomide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000698	0.00316	CcSEcCtD
Leflunomide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000688	0.00312	CcSEcCtD
Leflunomide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00306	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000658	0.00298	CcSEcCtD
Leflunomide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000653	0.00296	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000653	0.0161	CbGpPWpGaD
Leflunomide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000648	0.00294	CcSEcCtD
Leflunomide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00292	CcSEcCtD
Leflunomide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000636	0.00288	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—GRIA2—amyotrophic lateral sclerosis	0.000629	0.0156	CbGpPWpGaD
Leflunomide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000628	0.00284	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00283	CcSEcCtD
Leflunomide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00282	CcSEcCtD
Leflunomide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000617	0.0028	CcSEcCtD
Leflunomide—Pain—Riluzole—amyotrophic lateral sclerosis	0.000617	0.0028	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000608	0.015	CbGpPWpGaD
Leflunomide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000595	0.0027	CcSEcCtD
Leflunomide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00059	0.00268	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000584	0.0144	CbGpPWpGaD
Leflunomide—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000579	0.0143	CbGpPWpGaD
Leflunomide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000574	0.0026	CcSEcCtD
Leflunomide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00259	CcSEcCtD
Leflunomide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00259	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000556	0.0137	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—RAB5A—amyotrophic lateral sclerosis	0.000553	0.0137	CbGpPWpGaD
Leflunomide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000532	0.00241	CcSEcCtD
Leflunomide—DHODH—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00053	0.0131	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00053	0.0131	CbGpPWpGaD
Leflunomide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000518	0.00235	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000514	0.0127	CbGpPWpGaD
Leflunomide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00232	CcSEcCtD
Leflunomide—PTK2B—Endothelins—PLA2G4A—amyotrophic lateral sclerosis	0.000494	0.0122	CbGpPWpGaD
Leflunomide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00224	CcSEcCtD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000487	0.012	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000485	0.012	CbGpPWpGaD
Leflunomide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000477	0.00216	CcSEcCtD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—APOE—amyotrophic lateral sclerosis	0.000467	0.0115	CbGpPWpGaD
Leflunomide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000459	0.00208	CcSEcCtD
Leflunomide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000455	0.00206	CcSEcCtD
Leflunomide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000455	0.00206	CcSEcCtD
Leflunomide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000452	0.00205	CcSEcCtD
Leflunomide—DHODH—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000451	0.0111	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—MAPT—amyotrophic lateral sclerosis	0.000449	0.0111	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—SQSTM1—amyotrophic lateral sclerosis	0.000447	0.011	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP9—amyotrophic lateral sclerosis	0.000431	0.0107	CbGpPWpGaD
Leflunomide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000429	0.00194	CcSEcCtD
Leflunomide—DHODH—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000424	0.0105	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000416	0.0103	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—DAO—amyotrophic lateral sclerosis	0.000383	0.00948	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000355	0.00877	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000343	0.00848	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—IGF1—amyotrophic lateral sclerosis	0.000336	0.00831	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ATF1—amyotrophic lateral sclerosis	0.000303	0.00749	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00029	0.00718	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—amyotrophic lateral sclerosis	0.000276	0.00684	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSR—amyotrophic lateral sclerosis	0.000268	0.00663	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.000267	0.00661	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—CASP3—amyotrophic lateral sclerosis	0.000255	0.00632	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000252	0.00624	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—amyotrophic lateral sclerosis	0.000241	0.00597	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000234	0.00579	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00022	0.00544	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—amyotrophic lateral sclerosis	0.000219	0.00543	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—amyotrophic lateral sclerosis	0.000214	0.00529	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—SQSTM1—amyotrophic lateral sclerosis	0.000208	0.00515	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—amyotrophic lateral sclerosis	0.000206	0.00511	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000199	0.00491	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—amyotrophic lateral sclerosis	0.000194	0.0048	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000181	0.00447	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000167	0.00413	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000162	0.004	CbGpPWpGaD
Leflunomide—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000152	0.00375	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.00015	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000144	0.00355	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00014	0.00345	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000139	0.00343	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000136	0.00335	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000133	0.0033	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000129	0.0032	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000126	0.00312	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000119	0.00295	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000119	0.00295	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000118	0.00293	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000109	0.00269	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000108	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000107	0.00264	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	9.83e-05	0.00243	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	9.73e-05	0.00241	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—APOE—amyotrophic lateral sclerosis	8.95e-05	0.00221	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	8.94e-05	0.00221	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	8.9e-05	0.0022	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	8.58e-05	0.00212	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	8.58e-05	0.00212	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.45e-05	0.00209	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	8.31e-05	0.00206	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.27e-05	0.00205	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	8.26e-05	0.00204	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.95e-05	0.00197	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	7.87e-05	0.00195	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	7.84e-05	0.00194	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.78e-05	0.00192	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	7.6e-05	0.00188	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	7.6e-05	0.00188	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.6e-05	0.00188	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.53e-05	0.00186	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.3e-05	0.0018	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.29e-05	0.0018	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	7.19e-05	0.00178	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	7.07e-05	0.00175	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	6.86e-05	0.0017	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SQSTM1—amyotrophic lateral sclerosis	6.81e-05	0.00168	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	6.78e-05	0.00168	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.72e-05	0.00166	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.65e-05	0.00164	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.48e-05	0.0016	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.41e-05	0.00158	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ATF1—amyotrophic lateral sclerosis	6.38e-05	0.00158	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	6.2e-05	0.00153	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.13e-05	0.00152	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP9—amyotrophic lateral sclerosis	6.08e-05	0.0015	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	5.66e-05	0.0014	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.65e-05	0.0014	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.58e-05	0.00138	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.33e-05	0.00132	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB4—amyotrophic lateral sclerosis	5.2e-05	0.00129	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD40LG—amyotrophic lateral sclerosis	4.89e-05	0.00121	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.83e-05	0.00119	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.76e-05	0.00118	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	4.7e-05	0.00116	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.55e-05	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.4e-05	0.00109	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	4.34e-05	0.00107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	4.33e-05	0.00107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	4.33e-05	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—C3—amyotrophic lateral sclerosis	4.32e-05	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.13e-05	0.00102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.04e-05	0.000999	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.96e-05	0.00098	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.93e-05	0.000972	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	3.7e-05	0.000916	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	3.7e-05	0.000916	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.68e-05	0.000911	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.56e-05	0.000881	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.46e-05	0.000857	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.45e-05	0.000854	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	3.39e-05	0.000837	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.36e-05	0.000832	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.16e-05	0.000782	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.15e-05	0.000778	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	3.13e-05	0.000775	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.96e-05	0.000732	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.8e-05	0.000692	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.68e-05	0.000662	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.6e-05	0.000644	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.37e-05	0.000587	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	2.19e-05	0.000542	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.15e-05	0.000532	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.03e-05	0.000502	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.99e-05	0.000493	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.91e-05	0.000473	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.87e-05	0.000463	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.8e-05	0.000445	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	0.000435	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.7e-05	0.000422	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.66e-05	0.000409	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.64e-05	0.000406	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.56e-05	0.000387	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.54e-05	0.00038	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.45e-05	0.000358	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.4e-05	0.000347	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.4e-05	0.000347	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.12e-05	0.000278	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.06e-05	0.000263	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.92e-06	0.000245	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.67e-06	0.000239	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.61e-06	0.000238	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.88e-06	0.00022	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.26e-06	0.000204	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.59e-06	0.000188	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	7.31e-06	0.000181	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	6.25e-06	0.000154	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.01e-06	0.000124	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.28e-06	0.000106	CbGpPWpGaD
